Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Daoudlarian D, et al. Among authors: obeid m. Ann Oncol. 2024 Dec 17:S0923-7534(24)04979-2. doi: 10.1016/j.annonc.2024.12.004. Online ahead of print. Ann Oncol. 2024. PMID: 39701282 Free article.
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M. Joo V, et al. Among authors: obeid m. Nat Commun. 2024 Apr 30;15(1):3664. doi: 10.1038/s41467-024-47965-3. Nat Commun. 2024. PMID: 38693123 Free PMC article.
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Martins F, et al. Among authors: obeid m. Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0. Nat Rev Clin Oncol. 2019. PMID: 31092901 Review.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M. Boughdad S, et al. Among authors: obeid m. J Immunother Cancer. 2021 Oct;9(10):e003594. doi: 10.1136/jitc-2021-003594. J Immunother Cancer. 2021. PMID: 34686542 Free PMC article.
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G, Suffiotti M, Segot A, Noto A, Pantaleo G, Spertini O, Obeid M. Stalder G, et al. Among authors: obeid m. Haematologica. 2023 Jan 1;108(1):234-239. doi: 10.3324/haematol.2022.281221. Haematologica. 2023. PMID: 36073517 Free PMC article. Clinical Trial. No abstract available.
274 results